Skip to main content

Table 2 Clinicopathologic characteristics according to breast cancer phenotype

From: Succinate dehydrogenase expression in breast cancer

Parameters

Total n = 721 (%)

Luminal A n = 302 (%)

Luminal B n = 168 (%)

HER-2 n = 69 (%)

TNBC n = 182 (%)

P-value

n = 302 (%)

n = 168 (%)

n = 69 (%)

n = 182 (%)

Age (years, mean ± SD)

49.6 ± 10.9

50.6 ± 10.4

48.4 ± 10.0

52.4 ± 10.0

48.0 ± 12.4

0.005

Histologic grade

     

<0.001

 I

120 (16.6)

92 (30.5)

20 (11.9)

1 (1.4)

7 (3.8)

 

 II

364 (50.5)

182 (60.3)

91 (54.2)

36 (52.2)

55 (30.2)

 

 III

237 (32.9)

28 (9.3)

57 (33.9)

32 (46.4)

120 (65.9)

 

Tumor stage

     

0.007

 T1

350 (48.5)

167 (55.3)

85 (50.6)

30 (43.5)

68 (37.4)

 

 T2

356 (49.4)

127 (42.1)

81 (48.2)

38 (55.1)

110 (60.4)

 

 T3

15 (2.1)

8 (2.6)

2 (1.2)

1 (1.4)

4 (2.2)

 

Nodal stage

     

0.060

 N0

425 (58.9)

171 (56.6)

92 (54.8)

42 (60.9)

120 (65.9)

 

 N1

192 (26.6)

89 (29.5)

43 (25.6)

13 (18.8)

47 (25.8)

 

 N2

65 (9.0)

27 (8.9)

18 (10.7)

9 (13.0)

11 (6.0)

 

 N3

39 (5.4)

15 (5.0)

15 (8.9)

5 (7.2)

4 (2.2)

 

Estrogen receptor status

     

<0.001

 Negative

261 (36.2)

5 (1.7)

5 (3.0)

69 (100.0)

182 (0.0)

 

 Positive

460 (63.8)

297 (98.3)

163 (97.0)

0 (0.0)

0 (0.0)

 

Progesterone receptor status

     

<0.001

 Negative

346 (48.0)

49 (16.2)

46 (27.4)

69 (100.0)

182 (100.0)

 

 Positive

375 (52.0)

253 (83.8)

122 (72.6)

0 (0.0)

0 (0.0)

 

HER-2 status

     

<0.001

 Negative

573 (79.5)

302 (100.0)

89 (53.0)

0 (0.0)

182 (100.0)

 

 Positive

148 (20.5)

0 (0.0)

79 (47.0)

69 (100.0)

0 (0.0)

 

 Ki-67 LI (%, mean ± SD)

17.3 ± 18.4

4.7 ± 3.7

19.6 ± 12.6

19.3 ± 12.8

35.1 ± 23.0

<0.001

Tumor recurrence

63 (8.7)

14 (4.6)

13 (7.7)

11 (15.9)

25 (13.7)

0.001

Patient death

60 (8.3)

12 (4.0)

13 (7.7)

11 (15.9)

24 (13.2)

<0.001

Duration of clinical follow-up (months, mean ± SD)

70.0 ± 31.2

72.4 ± 29.3

70.2 ± 30.0

65.2 ± 34.3

67.8 ± 34.2

0.234

  1. TNBC triple negative breast cancer.